Bipartisan Senate Finance Framework Takes ‘Measured’ Aim At PBMs

Framework from Sens. Wyden and Crapo, looks like it would change, but not eliminate, the rebate system and gets an initial thumbs up from both the brand and generic drug lobbies.

Congress and middlemen
Legislation would not cut out the middleman. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

The bipartisan leadership of the Senate Finance Committee released a plan to tackle drugs costs that looks to go after but not completely gut the pharmacy benefits management industry.

The 20 April framework, which Sens. Ron Wyden, D-Ore., and Mike Crapo, R-Idaho, plan to use as the basis for proposed legislation, adds further momentum to the Congressional push...

More from Pricing Debate

More from Market Access